Physician profile
Jeffrey Steinberg
NPI 1538129259
$5,039.74
in general payments reported to CMS, 2019-2025
38 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,454 · 2020: $875 · 2021: $934 · 2022: $726 · 2023: $641 · 2024: $233 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Ih INC. | $928.87 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $846.39 | 2019-2023 | Aveed, Xiaflex |
| Antares Pharma, INC. | $565.25 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $459.19 | 2019-2023 | |
| Procept Biorobotics Corporation | $285.95 | 2023 | Aquabeam Robotic System |
| Boston Scientific Corporation | $194.24 | 2019-2023 | Rezum Generator |
| Teleflex LLC | $155.12 | 2021-2023 | Urolift |
| Janssen Biotech, INC. | $144.22 | 2019-2022 | |
| Acerus Pharmaceuticals Corporation | $138.75 | 2020-2022 | |
| 180 Medical, INC. | $107.46 | 2019-2024 | Gentlecath |
| Endo USA, INC. | $98.95 | 2024-2025 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $97.87 | 2022-2024 | Pylarify |
| Myriad Genetic Laboratories, INC. | $92.73 | 2021-2023 | Prolaris |
| Urovant Sciences INC | $84.25 | 2021-2022 | |
| Neotract INC. | $65.87 | 2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $64.68 | 2019-2022 | |
| Palette Life Sciences, INC. | $63.82 | 2022 | |
| Dentsply Ih Ab | $62.99 | 2022-2024 | Lofric |
| Merck Sharp & Dohme LLC | $51.42 | 2020-2023 | Keytruda, Lynparza |
| Telix Pharmaceuticals | $49.33 | 2024 | Illuccix |
| Coloplast Corp | $49.12 | 2020-2025 | |
| Hollister Incorporated | $44.00 | 2021-2022 | |
| Tolmar, INC. | $42.76 | 2024-2025 | Eligard, Jatenzo |
| Metuchen Pharmaceuticals | $37.82 | 2019 | |
| Zyla Life Sciences, INC. | $34.43 | 2019 | |
| Convatec INC. | $33.37 | 2024 | |
| Osiris Therapeutics INC. | $30.99 | 2019 | |
| Olympus America INC. | $29.93 | 2025 | Itind System |
| Blue Earth Diagnostics | $23.82 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.07 | 2022 | |
| Celgene Corporation | $21.77 | 2023 | Zeposia |
| C. R. Bard, INC. & Subsidiaries | $20.45 | 2019 | |
| Rochester Medical Corporation | $16.29 | 2020 | |
| Photocure INC | $16.28 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.97 | 2022 | |
| Accord Healthcare, INC. | $15.73 | 2022 | |
| Abc Home Medical Supply, INC. | $15.58 | 2025 | |
| Urogen Pharma, INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.